X4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results, Beats Expectations By $0.01 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) issued its quarterly earnings data on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01, Zacks reports. The company had revenue of $2.88 million for the quarter, compared to analyst estimates of $2.78 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%.

X4 Pharmaceuticals Stock Up 3.6%

XFOR opened at $3.18 on Friday. The company’s 50-day moving average is $3.23 and its 200 day moving average is $3.78. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 11.02. X4 Pharmaceuticals has a fifty-two week low of $2.43 and a fifty-two week high of $4.83.

Insiders Place Their Bets

In related news, President John Volpone sold 24,576 shares of X4 Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $109,117.44. Following the completion of the sale, the president owned 265,305 shares of the company’s stock, valued at $1,177,954.20. The trade was a 8.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO David Kirske sold 11,767 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total value of $33,653.62. Following the transaction, the chief financial officer directly owned 155,983 shares of the company’s stock, valued at $446,111.38. The trade was a 7.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 83,779 shares of company stock valued at $353,387 over the last three months. 1.13% of the stock is owned by company insiders.

Analysts Set New Price Targets

XFOR has been the topic of several research analyst reports. Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Wells Fargo & Company assumed coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They issued an “overweight” rating and a $11.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, X4 Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.